Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dihydroartemisinin-piperaquine versus quinine for Plasmodium malariae malaria in Mali
PACTR202610908810522Phase 2Completed
- Sponsor
- Université des Sciences, des Techniques et des Technologies de Bamako
- Start
- Jan 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dihydroartemisinin + piperaquine and quinine in malaria and Plasmodium malariae infection (2 arms), sponsored by Université des Sciences, des Techniques et des Technologies de Bamako. Started Jan 2025; status: completed.
02
Drugs
dihydroartemisinin + piperaquinequinine
03
Conditions
malariaPlasmodium malariae infection
Beyond the preview
Go deeper on PACTR202610908810522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202610908810522.